Oedien (Dienogest, Ethinylestradiol | Lactose Monohydrate)

Dienogest, the active ingredient in Oedien, is a synthetic progestogen presented as a combined oral tablet for systemic hormonal use. It treats estrogen‑dependent conditions, primarily menstrual‑related disorders, in women of reproductive age.

GNH USA supplies Oedien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oedien combines dienogest with ethinylestradiol to manage hormone‑responsive conditions. It is indicated for: - Dysmenorrhea: reduction of painful menstrual cramps. - Endometriosis‑associated pain: alleviation of chronic pelvic discomfort. - Contraception: prevention of ovulation and pregnancy when used as a combined oral contraceptive.

Adverse reactions may occur with Oedien and should be monitored.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: transient swelling or discomfort. - Weight gain: modest increase in body weight. - Mood changes: irritability or mild depressive symptoms. - Spotting: breakthrough bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Hypertension: new‑onset or worsening high blood pressure. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Visual disturbances: sudden loss of vision or eye pain. - Gallbladder disease: inflammation or stones.

Before prescribing Oedien, clinicians should evaluate patient history and risk factors. - Smoking status: avoid use in women >35 years who smoke. - Cardiovascular risk: assess for hypertension, clotting disorders, or heart disease. - Liver function: evaluate hepatic health before initiation. - Migraine history: caution in patients with migraine with aura. - Breast cancer history: contraindicated in active or past hormone‑sensitive malignancies. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Oedien may interact with several medication classes; monitoring is advised.

Major Interactions (Avoid): - Anticoagulants: may increase risk of thrombosis. - Antiepileptics (e.g., carbamazepine, phenytoin): reduce hormonal efficacy. - Rifampicin: decreases plasma levels of both hormones.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs/SNRIs): may heighten risk of bleeding. - Antibiotics (macrolides, tetracyclines): slight increase in hormone concentrations. - Herbal supplements (St. John’s wort): may lower contraceptive effectiveness.